92 related articles for article (PubMed ID: 12007619)
1. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection.
Mandal M; Lee KD
Biochim Biophys Acta; 2002 Jun; 1563(1-2):7-17. PubMed ID: 12007619
[TBL] [Abstract][Full Text] [Related]
2. Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.
Andrews CD; Huh MS; Patton K; Higgins D; Van Nest G; Ott G; Lee KD
Mol Pharm; 2012 May; 9(5):1118-25. PubMed ID: 22376145
[TBL] [Abstract][Full Text] [Related]
3. Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.
Ahlén G; Strindelius L; Johansson T; Nilsson A; Chatzissavidou N; Sjöblom M; Rova U; Holgersson J
PLoS One; 2012; 7(10):e46959. PubMed ID: 23071675
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation.
Andrews CD; Provoda CJ; Ott G; Lee KD
Bioconjug Chem; 2011 Jul; 22(7):1279-86. PubMed ID: 21612239
[TBL] [Abstract][Full Text] [Related]
5. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response.
Bouwer HG; Shen H; Fan X; Miller JF; Barry RA; Hinrichs DJ
Infect Immun; 1999 Jan; 67(1):253-8. PubMed ID: 9864223
[TBL] [Abstract][Full Text] [Related]
6. Mutants of listeriolysin O for enhanced liposomal delivery of macromolecules.
Walls ZF; Goodell S; Andrews CD; Mathis J; Lee KD
J Biotechnol; 2013 Apr; 164(4):500-2. PubMed ID: 23416330
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.
Johnston D; Reynolds SR; Bystryn JC
Cancer Immunol Immunother; 2006 Apr; 55(4):412-9. PubMed ID: 16151809
[TBL] [Abstract][Full Text] [Related]
8. Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy.
Hassan HA; Smyth L; Wang JT; Costa PM; Ratnasothy K; Diebold SS; Lombardi G; Al-Jamal KT
Biomaterials; 2016 Oct; 104():310-22. PubMed ID: 27475727
[TBL] [Abstract][Full Text] [Related]
9. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines.
Sun R; Liu Y
Hum Vaccin Immunother; 2013 May; 9(5):1058-68. PubMed ID: 23399758
[TBL] [Abstract][Full Text] [Related]
10. In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses.
Jenika D; Pounraj S; Wibowo D; Flaxl LM; Rehm BHA; Mintern JD
NPJ Vaccines; 2024 Jan; 9(1):18. PubMed ID: 38263169
[TBL] [Abstract][Full Text] [Related]
11. Novel adjuvants and vaccine delivery systems.
Morein B; Villacrés-Eriksson M; Sjölander A; Bengtsson KL
Vet Immunol Immunopathol; 1996 Nov; 54(1-4):373-84. PubMed ID: 8988882
[TBL] [Abstract][Full Text] [Related]
12. Preparation of glycopeptide-modified pH-sensitive liposomes for promoting antigen cross-presentation and induction of antigen-specific cellular immunity.
Yuba E; Gupta RK
Biomater Sci; 2024 Mar; 12(6):1490-1501. PubMed ID: 38329387
[TBL] [Abstract][Full Text] [Related]
13. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
14. Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes.
Arabi A; Aria Soltani S; Maniaci B; Mann K; Martinson H; Kullberg M
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140114
[TBL] [Abstract][Full Text] [Related]
15. A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy.
Shin JM; Song SH; Vijayakameswara Rao N; Lee ES; Ko H; Park JH
Biomater Res; 2018; 22():21. PubMed ID: 30128166
[TBL] [Abstract][Full Text] [Related]
16. Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity.
Bouma RG; Nijen Twilhaar MK; Brink H; Affandi AJ; Mesquita BS; Olesek K; van Dommelen JMA; Heukers R; de Haas AM; Kalay H; Ambrosini M; Metselaar JM; van Rooijen A; Storm G; Oliveira S; van Kooyk Y; den Haan JMM
Int J Pharm; 2024 May; ():124254. PubMed ID: 38795934
[TBL] [Abstract][Full Text] [Related]
17. Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines.
Yuba E; Kado Y; Kasho N; Harada A
J Control Release; 2023 Oct; 362():767-776. PubMed ID: 36244508
[TBL] [Abstract][Full Text] [Related]
18. Phosphorothioated DNA Engineered Liposomes as a General Platform for Stimuli-Responsive Cell-Specific Intracellular Delivery and Genome Editing.
Yan A; Chen X; He J; Ge Y; Liu Q; Men D; Xu K; Li D
Angew Chem Int Ed Engl; 2023 Jun; 62(25):e202303973. PubMed ID: 37100742
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of a recombinant listeriolysin O expressed in Escherichia coli and possible diagnostic applications.
Giammarini C; Andreoni F; Amagliani G; Casiere A; Barocci S; Magnani M
J Biotechnol; 2004 Apr; 109(1-2):13-20. PubMed ID: 15063610
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery.
Kim NH; Provoda C; Lee KD
Mol Pharm; 2015 Feb; 12(2):342-50. PubMed ID: 25521817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
